

Index

Note: Page numbers in *italic* indicate Figures and those in **bold** indicate Tables.

2×2 contingency table 487–488
95% confidence intervals (CIs) and
p-values 486

a

A-a gradient calculation 10
abdominal compartment syndrome
assessment for 81
causes and prognosis in neonates
and infants 236
definition and risk factors 314–315
in resuscitated burn patients 425
abdominal injury 307–315
abdominal paracentesis, performance
in the ICU 259–260
AC/VCV ventilation
auto-PEEP waveform and
intervention to correct 87, 87
high peak airway pressures in a
postoperative patient 83–84
intervention to improve
oxygenation 82
waveform analysis 88, 88
acetaminophen
clinical manifestations of acute
intoxication 175
features of hepatotoxicity
174–175
mortality in the United States 240
NAC antidote administration 240
prevention of hepatotoxicity in
overdose 240
treatment of acetaminophen
poisoning 175
acetylcholine, role in development of
delirium 129
acid-base balance 135–144

acid-base disorders
caused by vomiting 136
diabetic ketoacidosis 141
diagnosis of metabolic
acidosis 137
non-anion gap type metabolic
acidosis 140
see also metabolic acidosis;
metabolic alkalosis
acid burns, treatment 430
acidosis, “lethal triad” of
coagulopathy, acidosis, and
hypothermia 117
Acinetobacter species, beta-lactamase
production 105
activity scales 75
acute adrenal dysfunction, signs and
symptoms 146–147
acute carpal tunnel syndrome,
management 324–325
acute coronary syndrome with DAPT,
timing of future surgery
33–34
acute coronary syndromes 33–50
acute decompensated heart failure
(ADHF) 8, 9
acute fatty liver of pregnancy (AFLP),
diagnosis and
treatment 219–220
acute head injury, initial
management 277–279
acute kidney injury (AKI) 159–167
advantages of renal replacement
therapy 165–166
criteria for stage 3 AKI
159–160, **160**
definition 159, **160**

determining the cause using FENa
and FEUrea 166–167
diagnosis of intrinsic and prerenal
causes 163–164
diagnosis of prerenal
disorders 166
distinguishing intrinsic and
prerenal causes 164
distinguishing renal and prerenal
disorders 166–167
drugs associated with 165
effects of dopamine 165
effects of furosemide 164–165
etiologies 76
FENa calculation 166
indications for acute dialysis
162–163
indications for dialysis 161–162
initial workup for postoperative
oliguria 160–161
KDOGO criteria stages of AKI
159–160, **160**
nutritional management 167
potential perioperative causes 161
prevention of contrast-induced
nephropathy (CIN) 163
risk factors in pediatric ICU
patients 233
risk in elderly trauma patients
468–469
signs and symptoms of
hyperkalemia due to
stage 3 AKI 163
treatment of traumatic
rhabdomyolysis 162
acute liver failure, clinical features
and mortality risk 173–174

- acute lung injury (ALI)
 - associated with transfusion (TRALI) 110
 - pulmonary edema 14
- acute pericarditis 39–40, 39, 40
- acute phase proteins (APP)
 - functions of negative APPs 178–179
 - mediators involved in production of 177–178
 - response to severe injury 177
- acute phase response (APR) 177
- acute respiratory distress syndrome (ARDS)
 - additional therapies to decrease mortality 86–87
 - diagnosis in children 459–461, **460**
 - differences between pediatric and adult ARDS 229, 229
 - ECMO for ARDS 30
 - effect of PEEP in a severely hypoxic patients 6
 - immunonutrition
 - recommendations 183–184
 - location of optimal PEEP on a volume-pressure curve 13
 - pediatric patient *see* pediatric acute respiratory distress syndrome (PARDS)
 - positional therapy for severe ARDS 29–30
 - pulmonary edema 14
 - transmembrane fluid flux 14
- acute respiratory failure and mechanical ventilation 79–88
- acute stent thrombosis, diagnosis and treatment 440
- acute tubular necrosis, diagnostic criteria 160
- Addisonian crisis, signs and symptoms 146–147
- adnexal torsion, diagnosis and treatment 431
- adrenal insufficiency, after traumatic brain injury 148
- Advanced Trauma Life Support (ATLS) protocol, control of active bleeding 328–329
- Aeromonas* species, diagnosis of NSTI caused by 412
- age-related changes *see* elderly patients
- air leaks, sources in trauma patients 300–301
- airway management 69–78
 - emergency airway in pediatric patients 297
 - pediatric trauma patients 453
 - pregnant trauma patient 355
 - tracheal injury 297
- airway pressure release ventilation (APRV), effects on oxygenation 82–83
- albumin
 - effect on anion-gap type metabolic acidosis 143
 - use in pediatric burn patients 227–228
- alcohol dependence
 - risk of critical illness 133
 - risk of hospital mortality 133
- alcohol withdrawal pathophysiology 132–134
 - neurotransmitters responsible for 132
 - treatment 132–133, **133**
- alkali burns, initial treatment 430
- alpha error 485
- alvimopan (Entereg), prescribing limitations 98–99, **98**
- American Academy of Orthopedic Surgery (AAOS), guidelines for PE and bleeding prophylaxis 205–206, **206**
- American College of Chest Physicians (ACCP), VTE prevention and treatment guidelines 205, 206
- American Heart Association (AHA)
 - guidelines for CPR 15
 - recommendations for sudden cardiac arrest 17
- American Pediatric Surgical Association (APSA), guidelines for pediatric blunt trauma injury 234–235, 234
- American Society of Anesthesiologists (ASA), classification of physical status 71
- American Society of Regional Anesthesia and Pain Medicine (ASRA), guidelines on LMWHs and epidurals 204
- amino acids
 - administration of branched-chain amino acids in critically-ill patients 183
 - functions of arginine 180
 - functions of glutamine 178
 - functions of glutamine 180
 - requirements of critically-ill and injured patients 179
- amiodarone 15–16
- amniotic fluid embolism, diagnosis and treatment 221
- amniotic fluid embolism syndrome (AFES)
 - coagulopathy associated with 435
 - development of disseminated intravascular coagulation (DIC) 435
 - diagnosis and management 434–435
- amphetamine intoxication, symptoms and treatment 246–247
- amphotericin B, advantages of lipid formulations 102
- amphotericin B deoxycholate, renal toxicity 102
- amputation, risk in combined skeletal and arterial injuries 333–334, 334
- analgesia 121–128
 - delirium prevention strategies 130
 - postoperative pain in a patient with kidney disease 122
- anesthesia 121–128
 - causes of continued paralysis 70–71
 - indicators of malignant hyperthermia 126
 - malignant hyperthermia (MH) 77–78
 - postdural puncture headache 125–126
- anesthetic agents
 - for patients with liver disease 124
 - for patients with previous gastrectomy 124
 - for patients with vitamin B12 deficiency 124
 - potential hepatotoxicity 124
 - respiratory depression side effect 128
- angiotensin receptor blockers (ARB) 147
- ANOVA 485
- anterior mediastinal mass, anesthetic considerations 443
- antibiotic resistance
 - avoiding misuse and overuse of antibiotics 103–104

- extended-spectrum beta-lactamase (ESBL) microorganisms 95–96
 - mechanisms related to beta-lactamase production 105–106
 - risk factors for MDR pneumonia 96
 - antibiotics 100–108
 - black box warnings 108
 - choice based on risk of MDR VAP 104–105, **104**
 - duration of antibiotic therapy 90
 - effect on outcomes of sepsis 56
 - for ESBL organisms 105
 - for necrotizing soft tissue infection 95, 106–107
 - indications for combination therapy 92–93
 - interactions between NMBAs and aminoglycoside antibiotics 70–71
 - polyene antibiotic family 102
 - principles of antibiotic therapy 103–104
 - prophylactic antibiotics in critically-ill patients 93
 - treatment of extended-spectrum beta-lactamase-producing organisms 53
 - anticoagulants 99–100
 - anticoagulated trauma patients
 - management for surgery 33–34, **34**
 - management of intracranial hemorrhage following TBI 285–286
 - management of patients with HIT 100–101
 - patients with cirrhosis 210–211
 - rapid reversal of anticoagulation 118–119, **118**
 - rapid reversal of coagulopathy 114
 - antidepressant overdose, clinical
 - presentation of TCA toxicity 239–240
 - antidiuretic hormone (ADH)
 - deficiency following traumatic brain injury 145
 - lack of ADH release in central diabetes insipidus 135
 - antifungals, treatment for
 - cryptococcal meningitis 53–54
 - antiemetics, choice for critically-ill patients 99
 - antioxidants, supplementation in critically-ill patients 182–183
 - antiphospholipid syndrome (APS),
 - diagnosis and management 207
 - antiplatelet therapy, perioperative
 - management 116–117
 - antithrombin III deficiency 26
 - antithymocyte antibodies, side effects
 - when used as induction agents 216–217
 - aortic dissection
 - management of limited dissection 442
 - presentation 442
 - secondary complications 442
 - aortic injury
 - CXR findings 272
 - diagnosis following blunt trauma 304
 - diagnosis of traumatic aortic injury 305
 - treatment for traumatic aortic injury 305
 - APACHE II prognostic model,
 - applications 169
 - APACHE III prognostic model,
 - applications 169
 - apixaban, rapid reversal in trauma
 - patients 118–119, **118**
 - appendicitis
 - diagnosis 376
 - guidelines for laparoscopic appendectomy in pregnant patients 434
 - management options 376–377
 - presentation and diagnosis in pregnancy 433
 - treatment in elderly patients 470–471
 - treatment of acute appendicitis in pregnancy 433–434
 - appendix 371–383
 - carcinoid tumor 373
 - pseudomyxoma peritonei
 - symptoms and treatment 373
 - ARDS *see* acute respiratory distress syndrome
 - arginine, requirements in trauma and critical care patients 180
 - arrhythmias 33–50
 - multifocal atrial tachycardia (MAT) 80
 - arterial catheterization
 - complications 254
 - indications for 254
 - arterial line catheters, effects of
 - increasing distance from the heart 61
 - ascites, treatment for intractable
 - ascites in cirrhosis 173
 - asthma attack, respiratory failure and cardiomyopathy 36
 - asymmetric (skewed, non-parametric)
 - distribution 484, 484
 - atelectasis, signs of 80
 - atracurium
 - Hofmann elimination 97, **98**
 - reversal drugs 107
 - atracurium, mechanism of
 - action 123
 - atrial fibrillation, management in
 - elderly patients 472–473
 - atrial flutter 42–44, 43
 - atrial thrombus 43
 - attributable risk 487–488
 - autonomy principle 491, 493
 - competence to make decisions 493–494
 - right to choose therapy and who will deliver it 495–496
 - auto-PEEP, waveform and
 - intervention to correct 87, 87
 - Avalon Elite BiCaval Dual Lumen catheter, complications 28–29
- b**
- bacterial endocarditis, diagnosis and treatment 447–448
 - barbiturate therapy, use in
 - management of traumatic brain injury 194–195
 - bariatric surgery 415–422
 - causes of early mortality 420
 - recommendation for obesity 415
 - beneficence principle 491, 493, 499
 - benzamides, antiemetic action 99
 - benzocaine, methemoglobinemia
 - associated with 140
 - benzodiazepines
 - mechanism of action 101–102
 - treatment of overdose 101–102
 - use in the ICU for sedation 101–102

- beta blockers
 - overdose symptoms and management 247
 - role in postoperative myocardial infarction prevention 73
- beta error 485
- beta-lactam antibiotics 95–96
- beta-lactamase inhibitors 105–106
- beta-lactamases, microorganisms that produce 105–106
- Bezold–Jarisch reflex 48
- bile duct injury
 - factors in successful reconstruction 385
 - iatrogenic injury 385
- bile duct stones, MRCP imaging 266–267
- biliary anatomy 388
- biliary infection, empiric treatment regimen for specific patient populations 387
- bladder injury
 - associated with pelvic fractures 318, 318
 - extraperitoneal injury management 338
 - management of penetrating injury 337, 338
- bleeding risk, prophylaxis for total knee or hip replacement 205–206, **206**
- blood component therapy for transfusion 109
- blood glucose control, multiply-injured trauma patient 146
- blunt abdominal trauma
 - APSA guidelines for pediatric solid organ injury 234–235, 234
 - CT scan evaluation 263
 - hepatic or splenic blush on CT scan in pediatric patients 231
 - management of injuries in pediatric patients 235, 462
 - management of pediatric blunt kidney trauma 235
 - management of pediatric liver or spleen injury 234–235, 234
 - non-accidental trauma in young children 235
 - small bowel mesenteric injury 379–380, 379
- blunt cardiac injury (BCI), screening tools 304
- blunt cerebrovascular injury (BCVI)
 - 288–289, 289, **289**
 - diagnosis and management 277, 278
 - diagnostic imaging 268
 - indications for BCVI screening 290
 - indications for endovascular interventions 290–291, **290**
 - injury scale 290–291, **290**
- blunt neck trauma 287–297
- blunt trauma, splenic artery embolization caused by 263–264
- blunt vertebral artery injury, diagnosis and management 277, 278
- body mass index (BMI)
 - calculation 415
 - changes related to aging 472
 - classification 415, **416**
- Boerhaave's syndrome, diagnosis and treatment 359–360
- Bowel Injury Prediction Score (BIPS) 379–380
- bowel obstruction
 - gallstone ileus 388–389
 - Meckel's diverticulum 377, 377
- bowel perforation, symptoms in steroid-treated patients 149
- brachial artery injury
 - evaluation and management 330
 - presentation 330
- brain death
 - criteria for declaration 494–495
 - nonrational requests from the family 495
- brain injury *see* traumatic brain injury
- Brain Injury Guidelines (BIG) 284–285, **285**
- brain oxygenation monitoring techniques 195
- Brain Trauma Foundation, Guidelines for the management of severe traumatic brain injury 198
- branched-chain amino acids (BCCAs), administration in critically-ill patients 183
- broken heart syndrome 36
- bronchopleural fistula (BPF), complication of lung resection 441
- bronchoscopy
 - for diagnosis of ventilator-associated pneumonia 258
 - for Zone II penetrating neck trauma 294
- Brugada syndrome 35–36, 35
- bupivacaine (Marcaine), mechanism of action 72
- burn shock pathophysiology 423
- burns 423–430
 - abdominal compartment syndrome monitoring and treatment 425
 - albumin use in pediatric patients 227–228
 - area assessment 424
 - bladder pressure monitoring 425
 - burn center transfer criteria 428
 - burn shock pathophysiology 423
 - compartment syndrome diagnosis 425–426
 - compartment syndrome management 425–426, 426
 - compartment syndrome risk in circumferential burns 425–426
 - compromised chest wall movement and ventilation 85
 - deep second- and third-degree burns 429
 - elderly patients 473–474
 - escharotomy for compartment syndrome 425–426, 426
 - fluid resuscitation of burn patients 423
 - full-thickness circumferential burns of the torso 85
 - hyperkalemia risk 122
 - infection risk from central line catheters 426–427
 - inhalational injury treatment 428
 - initial resuscitation of burn victims 423
 - neuromuscular blocker choice for intubation 122
 - nutritional requirements of burn patients 427
 - nutritional therapy for burn patients 188
 - parenteral nutrition in severe burn patients 427
 - pediatric patients 462–463
 - percentage total body surface area involved 424

- potentially beneficial additional treatments 427
- resuscitation monitoring 424–425
- “rule of nines” used in area assessment 424
- scald burn treatment in a pregnant patient 436
- sequelae of initial burn injury 423
- side effects of topical antimicrobials 427–428
- signs of infection 426
- thoracic escharotomy 85
- topical agent for burned ear with exposed cartilage 429
- topical antimicrobials 429
- butyrophenones, antiemetic action 99
- C**
- C1 fracture, Jefferson fracture 295, 295
- C2 fracture, association with vertebral artery injury 295–296, 295
- caffeine, mechanism of action 250–251
- calcineurin inhibitors
 - adverse effects 210, 215
 - mechanisms of action 214–215
- calcineurin toxicity, caused by drug-drug interactions 209–210, **210**
- Candida glabrata*, antibiotic resistance 96
- Candida* species
 - association with CRBSI 63
 - intravascular infection risk factors and treatment 56
- candidemia in critically ill patients, treatment 56
- candidiasis
 - invasive, empiric antifungal therapy 106
 - postoperative, antibiotic prophylaxis 93
 - risk factors in critically-ill patients 106
- candiduria in critically ill patients, treatment 56
- “cannot intubate, cannot oxygenate” (CICO) scenario 293–294
- CaO₂ (oxygen content) of blood, calculation 18
- carbapenem-resistant microorganisms 95–96
- carbapenems, action against ESBL organisms 105
- carbon monoxide (CO) poisoning
 - mechanism 242
 - symptoms, treatment, and outcomes 242
- carcinoid tumor of the appendix 373
- cardiac allograft vasculopathy (CAV)
 - distinction for coronary artery disease (CAD) 213
 - medications to decrease CAV 213–214
- cardiac arrest
 - AHA recommendations for sudden cardiac arrest 17
 - AHA treatment guidelines 15
 - positive predictors of survival 15
 - suspected cardiac etiology 17–18
 - underlying causes of PEA arrest 16
 - unstable patient requiring pressor support 17–18
 - ventricular fibrillation following MI 49–50, 49
 - ventricular fibrillation treatment in the field 15–16
- cardiac arrhythmias, management in elderly patients 472–473
- cardiac cycle events 7–8, 7
- cardiac injury
 - mitral valve tene corda disruption 301
 - posttraumatic signs of internal cardiac injuries 301
 - prognostic indicators for penetrating injury 303
 - repair of cardiac laceration 303–304
 - screening for blunt cardiac injury (BCI) 304
- cardiac pacing, temporary transvenous cardiac pacemaker 255
- cardiac pressure-volume loops, physiologic processes represented 4, 4
- cardiac surgery, postoperative cardiac tamponade 442–443
- cardiac tamponade
 - diagnosis following penetrating injury 299–300
 - following cardiac surgery 442–443
- cardiac transplantation
 - cardiac allograft vasculopathy (CAV) diagnosis 213
 - medications to decrease CAV 213–214
- cardiogenic shock
 - features and etiology 20
 - role of endothelin-1 58
- cardiopulmonary resuscitation *see* CPR
- cardiothoracic injury 299–306
- cardiovascular collapse, indications for ED thoracotomy (EDT) 304–305
- cardiovascular physiology 3–14
- cardiovascular surgery 439–451
- cardiovascular system, age-related changes 469
- cardioversion, medications given after 41–42, 41–42
- carotid cavernous fistula
 - diagnosis 275, 276
 - initial treatment and management 275
- carpal tunnel symptoms, related to distal radius fracture 324–325
- case-control studies 486–487
- catheter-associated urinary tract infection (CAUTI), risk factors 93–94
- catheter-directed thrombolytics (CDT) for DVT 201
- catheter-related bloodstream infections (CRBSI)
 - common causative organisms 63
 - guidelines for prevention 62
 - prevention practices 94
 - treatment 53
- catheterized critically-ill patients, *Candida* infection risk and treatment 56
- caustic substance ingestion
 - esophageal injuries 449–450
 - evaluation of injuries 365
 - initial assessment and management 365–366
- cecal volvulus, diagnosis and management 378, 378
- cefepime, antimicrobial action 104, 105
- ceftazidime, antimicrobial action 105
- cell biology 209–217

- central cord syndrome, association with falls in the elderly 193
- central diabetes insipidus
 - after traumatic brain injury 145–146
 - free water deficit 135
 - pathophysiology and treatment 135
- central line catheters, managing
 - infection risk in burn patients 426–427
- central nervous system infections, antifungal treatment 53–54
- central pontine myelinolysis 139
- central venous catheter (CVC), timing of intravascular pressure measurement 66–67
- central venous catheter (CVC) placement
 - best practice guidelines 62
 - prevention of central line-associated bloodstream infection (CLABSI) 253
 - ultrasound guidance 270–271
 - ultrasound guidance versus the landmark technique 253–254
- central venous pressure (CVP)
 - cause of acute rapid rise 66
 - definition 66
- cerebral artery aneurysm
 - rupture causing subarachnoid hemorrhage 192
 - vasospasm following surgical or endovascular management 192
- cerebral blood flow, zone of normal cerebral autoregulation 196
- cerebral perfusion pressure (CPP), optimizing in traumatic brain injury 196, 283–284
- cerebral salt wasting syndrome (CSW) 139
- cerebrospinal fluid (CSF), penetration by antifungals 53–54
- cerebrospinal fluid (CSF) rhinorrhea, tests to detect 276
- cervical esophageal injury
 - evaluation 361–362
 - operative repair 362
- cervical necrotizing fasciitis, causes and treatment 413–414
- cervical spinal cord injury
 - initial management of blunt injuries 195
 - pulmonary function testing 288
- cervical spine, normal anatomical variation in children 457
- cervical spine clearance
 - in elderly patients 474
 - timing of 296–297
- cervical spine injury, diagnosis in children 457
- Cesarean section
 - in trauma patient undergoing CPR 436–437
 - prophylactic antibiotics 225
- CHA₂DS₂-VASc score 33, **34**
- CHADS₂ score 33
- chemical burns
 - initial treatment of strong alkali burns 430
 - treatment of acid burns 430
- chemical esophageal injuries 449–450
- chemotherapy
 - neutropenia complication 54
 - neutropenic enterocolitis complication 375
- chest compartment syndrome, signs and treatment 84–85
- chest trauma
 - indications for urgent/emergent thoracotomy 303
 - retained hemothorax 306
 - widened mediastinum following blunt trauma 304
- chest tube, sources of air leaks in trauma patients 300–301
- child abuse, signs of non-accidental trauma 458
- child protection services, notification of suspected child abuse 458
- Child–Turcotte–Pugh (CTP) prognostic model 169
- chi-square test 484
- cholecystectomy
 - indications for prophylactic procedure 385–386
 - laparoscopic method 385
- choledocholithiasis
 - management in pregnancy 389
 - treatment in Roux-en-Y gastric bypass patient 417–418
- Chvostek's sign 145
- ciprofloxacin, use in VAP 104–105
- cisatracurium
 - Hofmann elimination 97, **98**
 - mechanism of action 122
 - metabolism and elimination 72
 - reversal drugs 107
 - use for patients with liver or renal disease 122–123
- Citrobacter* species, beta-lactamase production 105
- clindamycin, interaction with neuromuscular blocking agents 70–71
- Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar) 133
- Clinical Pulmonary Infection Score (CPIS) 90
- clopidogrel 44
- Clostridium difficile*, postoperative infection
 - management 89–90
- Clostridium difficile* colitis
 - management 372
 - treatment of refractory infection 100
- coagulation 109–119
 - diagnosis and treatment of disseminated intravascular coagulation (DIC) 114
 - etiology of excessive bleeding after trauma or surgery 115
 - rapid reversal of anticoagulation in trauma patients 114, 118–119, **118**
- coagulation system, role in the sepsis-induced inflammatory cascade 57
- coagulopathy
 - bleeding in uremic patients 116
 - “lethal triad” of coagulopathy, acidosis, and hypothermia 117
- cocaine
 - intoxication symptoms and treatment 246–247
 - mechanism of action 250–251
- cocaine-associated chest pain (CACP), evaluation and management 246–247
- cohort studies 483, **483**
- colon 371–383
 - management of *Clostridium difficile* colitis 372

- postoperative complications of
 - destructive colon injuries 311
 - treatment of intraperitoneal gunshot wounds 375
 - colon tumor
 - chemotherapy for metastases 376
 - symptoms and management 376
 - colonic pseudo-obstruction, treatment 374
 - communication failures, risk factor for wrong-site surgical procedures 73
 - compartment syndrome
 - indication for a therapeutic decompressive fasciotomy 333
 - indications in closed tibia and fibula fracture 321
 - length of fasciotomy incision for the leg 322, 322,
 - management in burn patients 425–426, 426
 - medical malpractice liability issues 321–322
 - of the chest 84–85
 - pressure threshold for decompression 322
 - risk in burn patients 425–426
 - see also* abdominal compartment syndrome
 - compensatory anti-inflammatory response syndrome (CARS) 178–179
 - complicated skin and soft tissue infections (cSSTIs)
 - antibiotic choice 410–411
 - management 409
 - types of 409
 - component separation technique, for hernia repair 405
 - computed tomography *see* CT
 - confidence intervals (CI) in statistics 484
 - confounding in studies 487, 488
 - Confusion Assessment Management (CAM) tool 130, **131**
 - consequentialism 495
 - continuous renal replacement therapy, for volume status management 340
 - contrast-induced nephropathy (CIN) 76
 - prevention in elderly trauma patients 468
 - prevention strategies 163
 - CO-oximetry
 - blood constituents measured by 60
 - measurement of oxygen saturation (SpO₂) 59–60
 - COPD exacerbations, use of NIPPV 86
 - core body temperature, at levels of hypothermia 154
 - coronary artery bypass grafting (CABG), for acute coronary syndrome 44
 - coronary artery disease (CAD)
 - distinction from cardiac allograft vasculopathy (CAV) 213
 - smoking risk factor 49
 - corticosteroids, indications for use in septic shock 52
 - Cox proportional hazard ratio 487
 - CPR (cardiopulmonary resuscitation) 15–21
 - American Heart Association guidelines 15
 - percentage of myocardial and cerebral blood flow provided by 16–17
 - CRBSI *see* catheter-related bloodstream infections
 - cricothyrotomy
 - predictors of difficult cricothyrotomy 69
 - SMART assessment tool 69
 - critical oxygen delivery 13–14
 - critically-ill patients
 - Candida* intravascular infection risk and treatment 56
 - factors in successful fluid resuscitation 65–66
 - nutritional support 77
 - optimizing oxygen delivery (DO₂) 65
 - pharmacokinetic and pharmacodynamic principles 102–103
 - refeeding syndrome (RFS) 77
 - role of lactate clearance in successful fluid resuscitation 65–66
 - cross-sectional studies 483
 - cryptococcal meningitis, antifungal treatment 53–54
 - CT (computed tomography)
 - evaluation of blunt abdominal trauma 263
 - reducing radiation dose in children 464
 - CT angiography
 - blunt vertebral artery injury 277, 278
 - diagnostic evaluation of penetrating neck trauma 265
 - CT arteriography, use in penetrating peripheral vascular trauma 265–266
 - Cushing's syndrome 147
 - CXR, findings in traumatic aortic injury 272
 - cyanide toxicity
 - associated with nitroprusside treatment 247–248
 - symptoms and treatment 247–248
 - cyclizine, antiemetic action 99
 - cyclosporine
 - immunosuppression in transplant patients 210
 - mechanism of action 214–215
 - side effects 215
 - cystoprostatectomy, postoperative complications 339, 339
 - cytokine release syndrome, management in transplant patients 216–217
 - cytomegalovirus (CMV) infection
 - opportunistic infection in immunosuppressed patients 93
 - treatment in transplant patients 215–216
- d**
- D-dimer, diagnostic use in DVT and PE 203–204
 - dabigatran, rapid reversal in trauma patients 118–119, **118**
 - dalteparin, prophylactic use 203
 - damage-control laparotomy (DCL), concept and indications 312
 - damage-control surgery (DCS), aim of the second phase 313
 - data analysis, descriptive analyses 484, 484
 - decompressive craniectomy, in traumatic brain injury 283–284
 - decompressive craniotomy, for traumatic intracranial hypertension 197–198
 - DECRA trial (2011) findings 197–198

- deep vein thrombosis *see* DVT
- delirium 129–134
 - causes and risk factors 129
 - Confusion Assessment Management (CAM) tool 130, **131**
 - DSM-V diagnostic criteria 129
 - effects of medications 131
 - incidence in hospital and the ICU 129
 - long-term risks associated with 131–132
 - medications to avoid 467–468
 - prevention strategies in the ICU 130, 467
 - primary evaluation and management 130, 131
- delirium tremens
 - RASS evaluation **133**, 133
 - signs and symptoms 132
 - treatment of alcohol withdrawal 132–133, **133**
- Denver screening criteria for blunt cerebrovascular injury (BCVI) 288–289, 289, **289**
- deontology 491, 495
- depression in elderly people, suicide risk of tricyclic antidepressants (TCAs) 471
- descriptive analyses, features of 484, 484
- desflurane, metabolism 124
- desomorphine (Krokodil), effects of use as alternative to heroin 248–250
- dexmedetomidine, mechanism of action 102, 121–122, 128
- diabetes insipidus (DI), after traumatic brain injury 145–146
- diabetic foot infections
 - predominant pathogens associated with 413
 - presentation of severe SSTIs 413
- diabetic ketoacidosis
 - presentation and assessment 141
 - treatment in addition to insulin 150
- diagnostic imaging 261–272
- dialysis, indications for acute dialysis 162–163
- diaphragmatic injury, detection following penetrating trauma 301
- diazepam, mechanism of action 128
- Dieulafoy's lesion, diagnosis and management 368
- diffuse axonal injury, diagnosis 282
- digitalis toxicity, association with electrolyte abnormalities 138, 138
- dilaudid, mechanism of action 122
- diltiazem, drug-drug interactions 209–210, **210**
- diphenhydramine, antiemetic action 99
- disseminated intravascular coagulation (DIC)
 - associated with amniotic fluid embolism syndrome (AFES) 435
 - diagnosis and treatment 114
- distributive justice 491, 493
- diverticulitis, management according to the Hinchey staging system 371
- DO₂ (oxygen delivery)
 - calculation 18
- dobutamine, mechanism of action of vasodilatory effects 62
- domperidone, antiemetic action 99
- dopamine, effects in acute kidney injury (AKI) 165
- droperidol, antiemetic action and side effects 99
- drug-drug interactions
 - in transplant patients 209–210, **210**
 - neuromuscular blocking agents and aminoglycoside antibiotics 70–71
- drugs associated with acute kidney injury (AKI) 165
- Duke Activity Status Index (DASI) 75
- duodenum 359–369
 - management of obstructive duodenal hematoma 366–367
 - management of penetrating injury 367
 - symptoms and treatment of a perforated duodenal ulcer 363–364
- duplex ultrasound, evaluation of peripheral vascular trauma 328
- DVT (deep vein thrombosis)
 - catheter-directed thrombolytics (CDT) 201
 - diagnostic use of D-dimer 203–204
 - incidence and management 202–203
 - inferior vena cava (IVC) filter placement 255–256
 - post-thrombotic syndrome (PTS) 200
- DVT prophylaxis
 - effectiveness of IPC devices and GCSs 199–200
 - protocols for pelvic fracture 318–319
- e**
- ECG, multifocal atrial tachycardia (MAT) 80
- echocardiography, surgeon-performed in the ICU 271–272
- ECMO (extracorporeal membrane oxygenation) 23–31
 - bleeding from a previously non-draining chest tube 27–28
 - causes of acute change 31
 - choice between VA ECMO and VV ECMO 30
 - coagulopathy associated with 26
 - correcting acid-base abnormality 26–27
 - criteria for use in respiratory failure 29–30
 - distance between cannulas in VV ECMO 30
 - factors affecting patient survival 24–26, 25
 - Harlequin Syndrome 23–24, 29
 - in ARDS with sepsis 30
 - indicator of time to trial off ECMO 27
 - management of bleeding 27–28
 - patient selection 24–26, 25
 - pediatric patient
 - consequences of malpositioned veno-venous cannula 237–238, 238
 - management of massive hemothorax 236–237, 237
 - verification of correct placement of a veno-venous cannula 237–238, 238
- rate of sweep gas in the ECMO circuit 26–27

- recognising adequate support 24
- relative contraindications 23
- RESP score 25–26, **25**
- role in respiratory failure management 87
- signs and causes of recirculation 30
- use in acute hypoxic respiratory failure in trauma patients 26
- veno-arterial ECMO 23–24
- veno-venous ECMO 23–24
- ectopic pregnancy
 - presentation and diagnosis of ruptured ectopic pregnancy 431–432
 - risk factors 431–432
 - treatment of ruptured ectopic pregnancy 431–2
- edema, resuscitation fluids which promote edema 143–144
- edrophonium, cholinesterase inhibitor 107, 108
- eFAST (extended focused assessment sonography for trauma), injuries detected by 262–263
- EKG
 - left axis deviation 37–38
 - measuring SR elevation 39–40, 39, 40
 - ST segment elevation and PR segment elevation 39–40, 39, 40
- elderly patients
 - age-related cardiovascular changes 465, 469
 - age-related changes in nutrition and metabolism 472
 - appendicitis 470–471
 - cardiac arrhythmias 472–473
 - decision-making by surrogates 469–470
 - nutritional support in critical illness 471–472
 - presentation of peptic ulcer disease 470
 - prevalence and etiologies of syncope 473
 - prevalence of *H. pylori* infection 470
 - suicide rates 471
 - TCA overdose 471
- elderly trauma patients
 - avoiding delirium in the ICU 467–468
 - burn injuries 473–474
 - cervical spine clearance 474
 - effects of use of warfarin 466–467
 - incidence and consequences of rib fractures 465–466
 - loss of upper extremity motor function after a fall 193
 - mechanical ventilation 466
 - patient refusal of surgery 469–470
 - rapid reversal of anticoagulation 466–467
 - renal dysfunction 468–469
- electrolyte abnormalities
 - associated with digitalis toxicity 138, 138
 - associated with massive transfusion 113–114
 - caused by vomiting 136
 - diagnosis of hyponatremia 176
- electrolytes 135–144
- Eliquis *see* apixaban
- emergency department thoracotomy (EDT), indications for 304–305
- end-diastolic volume 4, 4
- end-of-life care 491–499
 - patient who may have impaired judgment 493–494
 - substituted judgment 491, 493–494
- end-organ perfusion, ways to promote 4–5
- endocarditis, diagnosis and treatment 447–448
- endocrinopathies 145–151
- endoscopy, considerations before performing in the ICU 258–259
- endothelin-1, role in cardiogenic shock 58
- endotracheal intubation
 - emergent intubation in pediatric patients 453–454
 - techniques for successful intubation 256
- enoxaparin
 - administration for pulmonary embolism 99–100
 - VTE prophylactic dosing and monitoring 207
- enteral nutrition (EN)
 - biochemical derangement in refeeding syndrome (RFS) 77
 - delivery in the ICU 186
 - in the critically-ill patient 77
 - monitoring in the ICU 186
 - tolerance in pediatric critical care patients 232
- Entereg (alvimopan), prescribing limitations 98–99, **98**
- Enterobacter* species
 - antibiotic to treat extended-spectrum beta-lactamase-producing strains 53
 - association with CRBSI 63
 - association with VAP 55, 96
 - beta-lactamase production 105
- Enterococcus* species, association with CRBSI 63
- envenomations 239–251
- epidural analgesia, and LMWHs 204
- epidural hematoma
 - diagnosis 281
 - surgical management of acute hematoma 281
- epigastric blunt injury, management of multiple injuries in children 461–462, 461, **461**
- epinephrine 15
- error types in statistics 485–486
- ESBL *see* extended-spectrum beta-lactamase
- escharotomy, for compartment syndrome in burn patients 425–426, 426
- Escherichia coli*, antibiotic regimen for ESBL *E. coli* 95–96
- esophageal balloon catheter values, interpretation 11
- esophageal injury
 - caustic substance ingestion 449–450
 - cervical esophageal injury repair 362
 - esophageal laceration repair 292
 - evaluation of cervical esophageal injury 361–362
 - gunshot wounds 364–365
 - management approaches 292–293
- esophageal perforation
 - antibiotic regimen 360–361
 - Boerhaave's syndrome diagnosis and treatment 359–360
 - causes 449, 449
 - iatrogenic 360, 449, 449
 - morbidity and mortality rates 360

esophageal varices, prevention of
variceal bleeding 172

esophagogastric anastomosis, diagnosis
of anastomotic leak 450

esophagoscopy, for Zone II
penetrating neck trauma 294

esophagus 359–369
anatomy 359
blood supply 359

ethical parity 491

ethical principles 491

ethics 491–499

ethylene glycol ingestion, toxicity and
treatment 243

etomidate
influence on postoperative
outcome 150
inhibition of adrenal steroid
production 124–125
risk of adrenal insufficiency 150

extended-spectrum beta-lactamase
(ESBL) organisms
antibiotic regimen for ESBL
Escherichia coli 95–96
antibiotics to treat 53
choice of antimicrobial
treatment 105

extracorporeal membrane
oxygenation *see* ECMO

extraperitoneal penetrating trauma
management 382

extraperitoneal rectal injuries,
recommended treatment
313–314

extubation
determinants for safe extubation
85–86
negative pressure pulmonary
edema 79–80
use of the rapid shallow breathing
index (RSBI) 85–86

f

Factor V Leiden mutation,
perioperative risk 205

falling, history of 36–37, 37

falls in the elderly, central cord
syndrome 193

family of deceased, nonrational
requests from 495

fasciotomy
length of incision to decompress the
leg compartments 322, 322
predictors of the need for 333

FAST exam (Focused Assessment
with Sonography for Trauma),
sensitivity and
specificity 269, 270

femoral hernia
borders that define the femoral
ring 404
comparison with inguinal
hernia 404
repair 404
repair options for incarcerated
hernia 406–407

femoral vein injury, options for
repair 332

fentanyl
mechanism of action 122
postoperative pain
management 98

fingers, replantation of traumatic
amputations 323

flail chest
cause and management 300
causes of hypoxia related
to 300
risk factors and management
450–451

flexible bronchoscopy, diagnostic
and therapeutic
indications 258

fluconazole, use in central nervous
system infections 53–54

fluid and electrolytes 135–144

fluid movement across capillary
membranes 14

fluid resuscitation, role of lactate
clearance in the critically-ill
patient 65–66

flumazenil, mechanism of action
101–102

fondaparinux, use in DVT
prophylaxis 202–203

Fournier's gangrene,
management 341

Frank–Starling law of the heart 4

free air in the chest and abdomen,
cause in steroid-treated
trauma patient 149

fulminant liver failure
clinical features and mortality
risk 173–174
treatment of acetaminophen
poisoning 175

functional capacity, pre-surgery
assessment 75

fungal infection in transplant
patients, antifungal
treatment 211

furosemide, effects in acute kidney
injury (AKI) 164–165

futile care, issues related to
continuation 496

g

gallbladder 385–392
cancer diagnosis and
management 390

gallbladder polyps, classification and
management 389–390

gallstone disease, management
during pregnancy 389

gallstone ileus, clinical presentation, diagnosis, and management during pregnancy 389–392

geriatrics 465–475
 Glasgow Coma Score
 determination for all injured patients 276–277, 277
 prediction of poor outcome in penetrating brain injury 191–192
 glutamate, role in alcohol withdrawal pathophysiology 132
 glutamine
 requirements in trauma and critical care patients 180
 role in nutritional support for critically-ill patients 178
 goal-directed echocardiography (GDE) examination, standard views 261–262
 graduated compression stockings (GCSs), effectiveness for DVT prophylaxis 199–200
 granisetron, antiemetic action 99
 Graves' disease, postoperative thyroid storm 148
 Greenfield filter, long-term follow-up of patients 207–208
 groin hernia, surgical evaluation for repair 403
 Guillain–Barré syndrome, diagnosis and therapy 197
 gunshot wounds
 brain injury 191–192
 control of pulmonary hemorrhage 444
 detection and treatment of ureteral injury 341–342, 342
 factors which help limb salvage 335, 335
 indications of underlying vascular injury 327
 management of esophageal injuries 364–365
 management of major vascular and musculoskeletal injuries 335, 335
 management of multiple penetrating injuries and bleeding 338–339, 339
 pediatric penetrating thoracic trauma 458
 predictor of poor outcome in brain injury 191–192
 revascularization of injuries 335, 335

treatment of intraperitoneal colon injury 375
 type of vascular injuries from shotgun wounds 334–335
 use of intravascular shunting 335, 335
 gynecologic surgery 431–437

h

Herhemphi ž, (a) 22((s) 2.9(p) 3ac) 2(u) 2(a) 9(tion) 2J3 2.263 Td 2yit

- heroin users, effects of use of
 - Krokodil alternative to heroin 248–250
 - hiatal hernia
 - symptoms and management 366
 - types of 366
 - high-frequency oscillation
 - ventilation, parenchymal-pleural fistula (PPF) management 82
 - hip dislocation, diagnosis and management 324
 - HIV
 - testing of patients 498
 - transmission risk for healthcare workers 498
 - HIV/AIDS patients, opportunistic infections 93
 - Hofmann elimination process 97, **98**
 - hospital-acquired infections, catheter-related bloodstream infections (CRBSI) 62, 63
 - hospital antibiograms, use in choice of antibiotic therapy for VAP 104
 - hydatid disease of the liver, cause and treatment 394
 - hydromorphone, postoperative pain management 97–98
 - hyperacute rejection, symptoms and management 213–214
 - hyperbaric oxygen (HBO) therapy, use as adjunctive treatment for NSTIs 413
 - hypercalcemia
 - definition and etiologies 140
 - symptoms and treatment 140
 - hyperglycemic hyperosmolar state (HHS), diagnosis and treatment 150–151
 - hyperkalemia
 - diagnosis and treatment 139
 - etiologies 139
 - indications for dialysis 161–162
 - prevention of malignant ventricular arrhythmias 164
 - risk associated with succinylcholine 137
 - signs and symptoms of stage 3 AKI 163
 - hypertension
 - appropriate choice of medication 147
 - preoperative medications to control 147–148
 - treatment during pregnancy 38 221–222
 - hypertensive emergencies 33–50
 - hyperthermia 153–157
 - effect of fever in brain injury 156
 - risk related to age 153
 - hypoalbuminemia, anion gap in ICU patients 143
 - hypocalcemia
 - presentation 141
 - risk after parathyroidectomy 145
 - with hypomagnesemia 141
 - hypocortisolism, signs and symptoms 146–147
 - hypoglycemia, from overdose of a hypoglycemic agent 244–245
 - hypomagnesemia
 - association with digitalis toxicity 138, 138
 - symptoms 16
 - with hypocalcemia 141
 - hyponatremia
 - causes and treatment 136
 - diagnosis and pathophysiology in cirrhosis 176
 - management of acute hyponatremia 139
 - symptoms of acute hyponatremia 139
 - treatment in edematous patients 136–137
 - hypophosphatemia, pathophysiology in critically-ill patients 141–142
 - hypotension in trauma patients
 - causes in intubated sedated patient 124–125
 - causes in trauma patients 293
 - indications for REBOA 314
 - intervention to maximize oxygen delivery (DO₂) 6
 - treatment for persistent hypotension in the ICU patient 137
 - hypothalamic-pituitary-adrenal (HPA) axis 148
 - hypothermia 153–157
 - cardiovascular and hemodynamic effects 156
 - changes in core body temperature 154
 - “lethal triad” of coagulopathy, acidosis, and hypothermia 117
 - metabolic consequences 157
 - perioperative risk and consequences 155–156
 - rewarming method and rate 154
 - role in mortality of trauma patients 117
 - role in perioperative complications 126
 - signs and symptoms 154
 - therapeutic 155, 157
 - hypotonic hyponatremia, causes and treatment 136
 - hypovolemic shock
 - diagnosis and treatment 21
 - hypotension caused by 293
 - oxygen extraction (O₂ER) calculation 19
 - ways to promote end-organ perfusion 4–5
 - hypoxemia, etiologies 10–11
- i**
- ICU, common procedures 253–260
 - idarucizumab, reversal agent for dabigatran 118–119, **118**
 - ideal body weight (IBW) calculation 416
 - idiopathic thrombocytopenic purpura (ITP), management 398–399
 - iliac vein injuries, factors affecting mortality and morbidity 310–311
 - imaging in pediatric patients, ways to reduce the total dose of radiation 464
 - immune-enhancing formulas
 - effects in critically-ill patients 184, 185
 - role of nucleotides 185
 - immune-suppressed patients, combination antibiotic therapy 92–93
 - immunology 209–217
 - immunonutrition
 - effects in critically-ill patients 185
 - recommendations for ARDS patients 183–184
 - immunosuppression in transplant patients 209–210, **210**

- incarcerated hernias 403–407
 para-colostomy hernia small bowel obstruction 406, 406
 repair options for femoral hernia 406–407
 umbilical hernia in patient with cirrhosis 381
- incidence, definition 486
- incisional hernia, principles for repair 405
- infectious disease 89–96
- Infectious Disease Society of America (IDSA), guidelines for management of VAP 104–105, **104**
- inferior vena cava (IVC) filter
 indications for 255–256
 management of a damaged filter 207–208
 potential complications 255–256
- inflammatory response to injury 51–58
- informed consent
 for participation in research studies 488
 in emergency situations 495
 issues in end-of-life care 495
 patient refusal of treatment 469–470
- inguinal hernia, comparison with femoral hernia 404
- inhalational burn injury, treatment 428
- injury and stress, phases of response to 177
- inotropic support, mechanism of action of dobutamine 62
- insulin therapy, multiply-injured trauma patient 146
- insurance companies, correction of incorrect claims 499
- intermittent pneumatic compression devices (IPCs), effectiveness for DVT prophylaxis 199–200
- interquartile range (IQR) 484
- interventional radiology 261–272
- intimate partner violence (IPV), risk factors and consequences in pregnancy 435
- intra-abdominal HTN, assessment for 81
- intra-abdominal hypertension, definition and risk factors 314–315
- intra-abdominal insufflation, physiologic changes caused by 76
- intra-abdominal pressure measurement, using bladder pressure 81
- intra-aortic balloon pump (IABP)
 complications 440–441
 indications, placement, and physiology 11–12
- intracranial hemorrhage, in anticoagulated elderly patients 466–467
- intracranial hypertension, common causes 189
- intracranial pressure (ICP)
 decompressive craniotomy 197–198
 DECRA trial (2011) findings 197–198
 decreasing ICP without lowering BP 284
 management of elevated ICP 190
 management of elevated ICP in pediatric trauma patients 196–197
 optimizing in traumatic brain injury 283–284
 RESCUEicp trial (2016) findings 197–198
 surgical management of uncontrollable elevation 197–198
 therapy for increased ICP in traumatic brain injury 280–281
 use of mannitol for osmotic therapy to reduce 190–191
- intracranial pressure (ICP)
 monitoring devices used for 193–194
 objective in traumatic brain injury 189–190
 severe traumatic brain injury patients 279
- intraparenchymal cerebral hematoma, indications for immediate surgery 190
- intravascular catheter-related infection, prevention practices 94
- intravascular volume status, indications from stroke volume variability (SVV) 60
- intravenous immunoglobulin (IVIG)
 treatment of NSTIs 412
 treatment of refractory *C. difficile* infection 100
- intubation
 identifying unrecognized misplaced intubation (UMI) 64–65
 Mallampati classification 69, 70, **70**
 modalities to improve success rate in Mallampati IV airway 69–70
 prediction of difficult intubation 69, 70, **70**
- invasive candidiasis
 empiric antifungal therapy 106
 risk factors for 106
- invasive zygomycosis, initial treatment 414
- ischemia reperfusion lung injury (IRLI), following lung transplant 215
- ischemic colitis diagnosis and management 380–381
- isoflurane, metabolism 124
- j**
- Jefferson fracture 295, 295
- Jehovah's Witness patient, management of splenic injury 401
- Jehovah's Witnesses, refusal of blood transfusion for a child 499
- k**
- Kaplan-Meier survival curve 488–489, 489
- Kcentra (PCC), use for rapid reversal of anticoagulation 114
- ketamine
 amnestic and analgesic effects 127–128
 dissociative anesthetic 127–128
 use in rapid-sequence intubation 72–73
- ketorolac, mechanism of action 122
- Klebsiella* species
 antibiotic resistance in *K. pneumoniae* 95–96
 association with CRBSI 63
 association with VAP 96

knee dislocation
 management of high-energy
 dislocation 322–323
 management of low-energy
 dislocation 323
 popliteal artery injury associated
 with 331–332
 Krokodil (Crocodile, Krok, Croc),
 effects of use as alternative to
 heroin 248–250
 Kruskal-Wallis test 485

I

laboratory risk indicator for
 necrotizing fasciitis (LRINEC)
 score 341, 411, **411**
 lactic acid, role of lactate clearance in
 successful fluid
 resuscitation 65–66
 laparoscopic cholecystectomy 385
 early versus delayed
 procedure 386
 laparoscopy, physiologic changes
 caused by intra-abdominal
 insufflation 76
 Law of LaPlace 5
 left anterior fascicular block (LAFB),
 EKG deviation 37–38
 left ventricular pseudoaneurysm
 38–39, 38
Legionella pneumophila
 infection 55
 lidocaine 15–16
 effects of addition of
 epinephrine 72
 mechanism of action 72
 life-saving therapy, patient refusal
 of 491
 lightning strike victims
 initial concerns and management
 428–429
 most common cause of
 death 429
 neurologic sequelae 429
 linezolid, use in VAP 104–105
 lipid administration in critically-ill
 patients 182
 lisinopril, mechanism of action 147
 lithium overdose, toxic effects and
 treatment 242–243
 liver 393–398
 anatomy 396–397, 396
 liver abscess, pyogenic and amebic
 types 393

liver cirrhosis
 diagnosis of hepatopulmonary
 syndrome 175–176
 effect on morbidity and mortality
 in trauma patients 395–396
 fluid leakage from umbilical
 hernia 404–405
 hyponatremia diagnosis and
 pathophysiology 176
 management of esophageal
 varices 170
 management of hepatic
 encephalopathy 171–172
 management of intractable
 ascites 173
 management of persistent
 bleeding 173
 management of pulmonary
 embolism 210–211
 management of upper
 gastrointestinal bleeding 170
 prognostic models for surgical
 patients 169, **170**
 risk of increased morbidity and
 mortality after surgery
 397–398, **397**
 symptoms and treatment of *Vibrio*
vulnificus infection 211–212
 liver cirrhosis and ascites,
 incarcerated/strangulated
 umbilical hernia 381
 liver disease, pathogenesis of
 hepatorenal syndrome
 170–171
 liver failure 169–176
 clinical features and mortality
 risk 173–174
 distinction between prerenal
 azotemia and hepatorenal
 syndrome 209
 nutritional therapy 187
 treatment of acetaminophen
 poisoning 175
 liver injury
 abdominal computed tomography
 (CT) 393–394, 394
 APSA guidelines for pediatric blunt
 trauma 234–235, 234
 bile leak following laparotomy and
 hepatorrhaphy 309
 blush on CT scan 308
 criteria for nonoperative
 management 307
 delayed complications 395

indications for angiography and
 possible embolization 308
 nonoperative management
 393–394, 394
 post-injury biloma
 complication 394–395
 post-injury hemobilia 395
 liver transplantation
 diagnosis of hepatic artery
 thrombosis (HAT) 217
 indications and
 contraindications 214
 indications and outcomes
 173–174
 use of calcineurin inhibitors 210
 liver trauma
 management of blunt trauma 393
 nonoperative management 393
 liver tumors
 classification as benign or
 malignant **397**, 397
 types of **397**, 397
 local anesthetics
 amino ester and amino amide
 types 126
 early clinical signs of central
 nervous system toxicity 125
 ester and amide types 72
 mechanism of action 71–72
 lorazepam, mechanism of action
 101–102
 low-molecular-weight heparin
 (LMWH) anticoagulation
 99–100
 epidural analgesia and 204
 prophylactic use 203
 lower extremity ulceration, illicit drug
 likely to cause 248–250
 lower gastrointestinal bleeding,
 management 375–376
 LRINEC score 341, 411, **411**
 lumbar puncture
 complications 260
 use in the ICU 260
 lung resection, acute bronchopleural
 fistula (BPF)
 complication 441
 lung transplantation
 causes of postoperative
 pneumonia 216
 etiology of respiratory failure 215
 risk of ischemia reperfusion lung
 injury (IRLI) 215
 lungs, West lung zones 12

m

- mafenide acetate antimicrobial, side effects 427–428
- magnesium sulfate 15
- malignant gastric outlet obstruction, management 364
- malignant hyperthermia (MH)
 - causes, symptoms, and treatment 77–78
 - indicators of 126
- malignant ventricular arrhythmias, prevention in severe hyperkalemia 164
- Mallampati classification 69, 70, 70
- Mallory-Weiss tear, definition and management 361
- mannitol, use in osmotic therapy to reduce intracranial pressure 190–191
- Mann-Whitney U test 487
- massive transfusion
 - blood component therapy 109
 - definition 111–112
 - electrolyte abnormalities
 - associated with 113–114
 - hypocalcemia associated with 113–114
 - plasma for patient of unknown blood type 112–113
 - ratio and type of platelets 113
- massive transfusion protocol (MTP) 329
 - activation criteria 111–112
 - for pediatric patients 455–456
- McNemar's test 485
- MDMA (Ecstasy/Bath salts), mechanism of action 250–251
- mean (measure of central tendency) 484
- mechanical ventilation *see* ventilator support
- Meckel's diverticulum, diagnosis and management 377, 377
- median (measure of central tendency) 484
- mediastinitis, postoperative
 - initial management 89
 - microorganism associated with 89
- medical errors, disclosure and liability 497–498
- medical insurance, correction of incorrect claims 499
- medical malpractice, liability issues in compartment syndrome 321–322
- medical professionalism 495–496
- medical research, justification for performing 493
- medications, effect on risk of heat-related illness 156–157
- melen, presenting sign of PUD in elderly patients 470
- meperidine
 - mechanism of action 122
 - postoperative pain management 98
- meropenem, antimicrobial
 - action 105
- mesenteric ischemia (NOMI), identification and management 474–475
- mesenteric venous ischemia
 - associated with thrombosis 380, 380
- metabolic acidosis
 - anion gap type 141, 143
 - effect of albumin on anion-gap type 143
 - diagnosis and assessment 137
 - indications for use of sodium bicarbonate 167
 - non-anion gap type 140, 141
- metabolic alkalosis, causes 136
- metabolic equivalents (METS)
 - measure of functional capacity 75
- metabolic illness 145–151
- metabolism, effects of aging 472
- methanol ingestion, toxicity and treatment 243
- methemoglobinemia
 - diagnosis and treatment 139–140
 - drugs associated with 140
 - etiologies and treatment 123–124
- methicillin-resistant *Staphylococcus aureus* (MRSA) *see* MRSA
- methicillin-susceptible *Staphylococcus aureus* (MSSA) 89, 96
- metoclopramide, antiemetic
 - action 99
- metoprolol overdose, symptoms and management 247
- metronidazole, use in VAP 104–105
- micronutrients, supplementation in critically-ill patients 182–183
- midazolam
 - hemodynamic side effects 72–73
 - mechanism of action 101–102, 128
- Model for End-stage Liver Disease (MELD) risk scoring system 169, 170
- moral judgment, *prima facie* concept 492–493
- Moraxella* species, association with VAP 96
- morphine
 - mechanism of action 122
 - postoperative pain management 97–98
- motor bike accident trauma patient, evaluation and management 281–282
- MRCP (magnetic resonance cholangiopancreatography), preoperative detection of common bile duct stones 266–267
- MRSA (methicillin-resistant *Staphylococcus aureus*)
 - association with VAP 55, 96
 - risk factors for VAP 104–105, 104
- MRSA soft tissue infections, predictor of treatment failure and hospital mortality 410
- MSSA (methicillin-susceptible *Staphylococcus aureus*) 89, 96
- multidrug resistant (MDR)
 - pathogens, risk factors in VAP 104–105, 104
- multidrug resistant (MDR)
 - pneumonia, risk factors for 96
- multifocal atrial tachycardia (MAT), ECG trace and treatment 80
- multi-organ dysfunction syndrome (MODS), definition 51
- multivariable analyses 484
- multivariable linear regression 487
- multivariable logistic regression 487
- munificence 491
- muscle protein catabolism in critically-ill and injured patients 179
- Mycoplasma* infection 55
- myelinolysis 139

- myocardial infarction (MI)
 - complications 40–41, 40
 - complications after 48–49
 - perioperative preventive medication 73
 - right-sided ventricular infarction 45–48, 46, 47
 - ventricular fibrillation following 49–50, 49
- myocardial oxygen consumption (MVO₂), factors influencing 5
- myonecrosis, most common cause 411–412
- myxedema coma, diagnosis and treatment 151
- n**
- near infrared spectroscopy (NIRS)
 - monitoring of pediatric critical care patients 228
 - tissue oxygenation assessment 228
- neck
 - vascular anatomy 287, 288
 - zones of the neck 287, 288
- neck trauma 287–297
 - anterior Zone II stab wound 289–290
 - blunt cerebrovascular injury (BCVI) 288–289, 289, **289**
 - “clothesline” injury
 - management 297
 - indications for BCVI
 - screening 290
 - operative versus non-operative management 287, 288
 - repair of esophageal laceration 292
 - repair of tracheal laceration 292
 - seatbelt sign 288–289, 289, **289**, 290
 - tracheal injury 289–290
 - Zone II penetrating trauma
 - management 287–288, 294
- necrotizing fasciitis
 - cervical necrotizing fasciitis 413–414
 - choice of antibiotic 106–107
 - laboratory risk indicator (LRNEC) score 411, **411**
 - most common cause 411–412
- necrotizing pancreatitis
 - antibiotic prophylaxis 392
 - diagnosis and treatment approaches 390–391
- necrotizing soft tissue infections (NSTIs) 409–414
 - antibiotic choice 106–107
 - antibiotic regimen 95
 - causative organisms 94–95
 - classification 95, 412
 - diagnosis 409–410, 410
 - diagnosis of *Vibrio* or *Aeromonas* infection 412
 - hard signs 409, 410
 - hyperbaric oxygen (HBO) therapy 413
 - IVIG therapy 412
 - microbiologic etiologies 412
 - negative-pressure wound therapy (NPWT) 412
 - perineal region 341
 - signs 94–95
- negative pressure pulmonary edema, following extubation 79–80
- negative-pressure wound therapy (NPWT), use in NSTI management 412
- neostigmine, action as NMBA reversal agent 107, 108
- nephrogenic diabetes insipidus, diagnosis 145
- neurocritical care 189–198
- neurogenic shock
 - diagnosis, etiology and treatment 21
 - hypotension caused by 293
- neuromuscular blocking agents (NMBAs)
 - causes of continued paralysis 70–71
 - choice for burn victims 122
 - choice in patients with hepatic and/or renal dysfunction 97, **98**
 - choice of appropriate agent 72
 - effects of inadequate reversal 79
 - for critically-ill patients with liver or renal disease 122–123
 - interaction with aminoglycoside antibiotics 70–71
 - methods of elimination 97, **98**
 - patient with a contraindication to succinylcholine 123
 - reversal agents 107
 - risk factors for inadequate reversal 79
- neurotrauma 275–286
- neutropenia, treatment of infections 54
- neutropenic enterocolitis, complication of chemotherapy 374–375
- Nimbex *see* cisatracurium
- nitric oxide (NO), role in vasodilation 57–58
- nitroprusside, cyanide toxicity
 - associated with 247–248
- nitrous oxide, risks for patients with vitamin B12 deficiency 124
- non-accidental trauma in children
 - blunt abdominal trauma 235
 - reporting suspicious cases 458
- non-ethanol alcohols, toxicity and treatment 243
- non-invasive positive pressure ventilation (NIPPV)
 - contraindications 86
 - method and uses 86
- non-invasive ventilation (NIV), effects in the immediate postoperative setting 79
- nonmaleficence 491, 493
- nonmalefeasance 491
- non-occlusive mesenteric ischemia (NOMI), identification and management 474–475
- non-parametric (asymmetric, skewed) distribution 484, 484
- non-parametric tests of significance 485
- nonrational requests from patient’s family 495
- nonrational thinking 491
- normal (parametric) distribution 484, 484
- normal saline (0.9% NaCl solution), effect on plasma volume 144
- nosocomial infections, common pathogens 105–106
- nucleotides
 - functions of 185
 - role in immunonutrition 185
- null hypothesis, criteria for rejection 485–486
- nutrients, location of absorption within the GI tract 419–420
- nutrition
 - effects of ageing 472
 - requirements of children compared to adults 459
- nutritional support
 - deficiencies after bariatric surgery 419, 420

- for critically-ill elderly patients
 - 471–472
- in acute kidney injury (AKI) 167
- in critically-ill patients 177–188
- preferred routes 77
- refeeding syndrome (RFS) 77
- requirement of burn
 - patients 427
- nutritional therapy
 - burn patients 188
 - in hepatic failure 187
 - in pulmonary failure 186–187
 - obese critically-ill patients 188
 - severe pancreatitis 187–188

O

- obese patients 415–422
 - body mass index (BMI)
 - classification 415, **416**
 - effects of obesity on pulmonary
 - physiology 415
 - increase in prevalence of
 - obesity 415
 - nutritional therapy for critically-ill
 - patients 188
 - recommendation for bariatric
 - surgery 415
- risanketone 652MC 6.911nof ob(tr)2u(c)8(iveg s56.1l(e)4(e)6(p ra)9(n(e)8.9(c)T)0.765 Tw 2 1.263 Td(Oe)SAS))TJ)/SpanActualTextEFF20033
- ildafortidil volumeg sct79(ings)TJ)/SpanActualTextEFF20033BDC ()TjEMC 134828 0 Td()Tj14828 1.263 Td(416)Tj 1.263 TdObtneutrcn crit

pediatric critical care 227–238
 pediatric massive transfusion
 protocol 455–456
 pediatric trauma patients
 airway management 453–454
 blood transfusion for children of
 Jehovah's Witnesses 499
 emergency airway 297
 emergent endotracheal
 intubation 453–454
 evaluation of injuries from caustic
 substance ingestion 365
 initial assessment following caustic
 ingestion 365–366
 management of elevated ICP in
 traumatic brain
 injury 196–197
 mechanisms of fatal injury 456
 non-accidental trauma 456, 458
 normal ranges for vital
 signs 456–457, **456**
 nutritional requirements 459
 reporting suspected non-accidental
 trauma 458
 surgery 453–464
 PEEP *see* positive end-expiratory
 pressure
 pelvic angiography
 possible complications 264–265
 use in pelvic fracture 264
 pelvic fractures
 application of a pelvic binder or
 sheet 317, 318
 causes of bleeding associated with
 317–318
 diagnostic use of pelvic X-ray 271
 DVT prophylaxis
 protocols 318–319
 indicators of urethral injury 308
 management of hypotension
 associated with 307–308
 types associated with bladder
 injury 318, 318
 pelvic inflammatory disease, causes,
 diagnosis, and treatment
 432–433
 pelvic ring injuries, common
 symptoms and problems in
 women 319
 penetrating neck trauma 287–297
 diagnostic evaluation with CT
 angiography 265
 penetrating peripheral vascular trauma
 evaluation and management 266
 use of CT arteriography 265–266

penetrating torso trauma, use of
 triple contrast CT scans
 267–268
 penicillin-allergic patient, antibiotic
 choices 414
 peptic ulcer disease (PUD)
 causes 362–363
 presentation in elderly patients 470
 treatment of bleeding from
 ulcers 362–363
 percutaneous coronary intervention
 (PCI), effect on subsequent
 non-cardiac surgery 75
 percutaneous endoscopic
 gastrostomy (PEG) tube
 considerations for tube
 placement 259
 esophageal perforation 449, 449
 perianal hematoma, diagnosis and
 management 381–382
 pericardial effusion, assessment via
 transthoracic echocardiography
 (TTE) 261
 periclavicular gunshot wound,
 evaluation 302–303
 perilunate dislocation, avoiding delay
 in diagnosis and
 management 325
 perineum, management of penetrating
 traumatic injury
 treventiot
 ple(in,)Jurg3 pematve
 cmali7cationt

aent((Iy)9VSE) v295“303

perp(ur(al(v)(a)2(s)52.9(c)(ul)(ar in)9.1(jur)(y)13 1.263 TdEp)(enef)
 (c)(t)6.1(r(s ef)(f)6.1(e)4(c)69(tinc sur)2.9(v)(v)(at)
 cdueic,s and(managemen)9(t)/SpanActualTextE

- portal-systemic encephalopathy, pathophysiology and treatment 171–172
- positive end-expiratory pressure (PEEP)
effect in a severely hypoxic patient with ARDS 6
effect in patients who have ARDS 9
optimal location on a volume-pressure curve 13
- positive pressure ventilation, effects on cardiac function 5–6
- postdural puncture headache, symptoms and treatment 125–126
- postoperative acute respiratory failure, most likely cause 79
- postoperative *Candida glabrata* infection, antifungal treatment 96
- postoperative candidiasis, antibiotic prophylaxis 93
- postoperative *Clostridium difficile* infection, management 89–90
- postoperative mediastinitis
initial management 89
microorganism associated with 89
- postoperative mortality, medications likely to decrease mortality risk 93
- postoperative myocardial infarction, preventive medication 73
- postoperative nausea and vomiting, antiemetics 99
- postoperative oliguria, initial workup 160–161
- postoperative pain management, choice of analgesic 97–98
- postpartum patient
causes of hypotension, hypoxemia, and/or hemorrhage 434–435
endometriosis diagnosis and treatment 225
risk of VTE 201–202
- postpartum septic pelvic thrombophlebitis, diagnosis and management 223–224
- post-thrombotic syndrome (PTS), pathophysiology and management 200
- power of a study sample 483–484
- Pradaxa *see* dabigatran
- prealbumin, function as a negative acute phase protein 178–179
- Precedex *see* dexmedetomidine
- pregnancy
cardiovascular changes during 11
management of
choledocholithiasis 389
management of gallstone disease 389
respiratory and metabolic changes 221
risk of VTE 201–202
safe antihypertensive medications 38
- pregnant patient 345–357
airway management 355
cardiotocographic monitoring after blunt trauma 345
causes of hypotension, hypoxemia, and/or hemorrhage 434–435
characteristics of VTE in pregnancy 223
CPR and emergent Cesarean section 436–437
diagnosis and treatment of pulmonary embolism 224–225
differential diagnosis for altered mental state (AMS) 352
fetal risk of critical care medications 222
fetal survival in maternal cardiac arrest 437
guidelines for laparoscopic appendectomy 434
hemolytic uremic syndrome (HUS) 222–223
hypercoagulability of pregnancy 349–350
imaging radiation exposure concerns 348–349
imaging risks and considerations 267
incidence and types of trauma in pregnancy 356
indications for emergency Cesarean section 349
initial assessment and treatment of trauma patients 436
management changes in initial evaluation and resuscitation 353
management of neurologic injury 348
- mortality rate for trauma during pregnancy 356
- normal laboratory studies in pregnancy 355–356
- perimortem emergency C-section procedure 351–352
- physiological changes associated with pregnancy 346–347
- posterior reversible encephalopathy syndrome (PRES) 225
- presentation and diagnosis of acute appendicitis 433
- risk and consequences of intimate partner violence (IPV) 435
- risk of intimate partner violence 351
- risk of placental abruption and fetal demise 353–354
- risk of thromboembolism in pregnancy 349–350
- routine
assessment
of fetal well-being 354–355
- seat belt use by pregnant women 350–351
- thrombotic thrombocytopenic purpura (TTP) 222–223
- tocolytic associated pulmonary edema 226
- tocolytic medications to prevent premature labor 345–346
- treatment of acute
appendicitis 433–434
treatment of HELLP syndrome 352–353
treatment of scald burn injuries 436
- use and interpretation of the Kleihauer-Betke test 347–348
- uterine rupture caused by trauma 356–357
- pre-renal azotemia
distinction from acute tubular necrosis 160
distinction from hepatorenal syndrome (HRS) 209
- pressure-volume dysregulation, “bird’s beak” phenomenon 88, 88
- preterm labor, tocolytic-associated pulmonary edema 226
- prevalence, definition 486

prima facie nature of principles and moral rules 492–493

principlism 491, 495

prisoners of war (POWs), ethical and humane treatment by physicians 492

prochlorperazine, antiemetic action and side effects 99

professional conduct in patient care 495–496

progesterone, use in traumatic brain injury treatment 196

prognostic models, for surgical patient with liver cirrhosis 169, **170**

prolonged QT interval 42, 42

propofol

- common side effects 121
- hemodynamic side effects 72–73
- mechanism of action 121, 128
- metabolism 124

propofol infusion syndrome 125

protein synthesis

- in critically ill and injured patients 179

process of mRNA

- translation 179–180
- sites of 179–180

prothrombin complex concentrate (PCC)

- for rapid reversal of anticoagulation 114, 118–119
- use to normalize INR 61–62

protocolized emergency department sepsis guideline 227

Pseudomonas aeruginosa

- antibiotic resistance 95–96
- association with VAP 55, 96
- beta-lactamase production 105–106
- choice of antimicrobial medication 105–106
- duration of antibiotic therapy for VAP 90
- risk factors for MDR *Pseudomonas* VAP 104–105, **104**
- use of combination antibiotic therapy 92–93

pseudomyxoma peritonei, symptoms and treatment 373

psychiatric disorders 129–134

- psychosis etiologies 134
- psychosis presentations and management 133–134

pulmonary artery catheter (PAC)

- false cardiac output measurement caused by cardiac abnormalities 62–63
- indications and contraindications for placement 63–64, 254–255
- information provided by 254–255
- pressure changes as the catheter is being placed 61–62
- thermodilution principle 62–63

pulmonary edema

- following myocardial infarction 40–41, 40
- in ALI/ARDS 14
- re-expansion pulmonary edema 445
- tocolytic-associated pulmonary edema 226

pulmonary embolism (PE)

- AAOS recommendations for prophylaxis 205–206, **206**
- diagnosis and treatment in a pregnant patient 224–225
- diagnostic scoring systems 204
- diagnostic use of D-dimer 203–204
- enoxaparin administration 99–100
- following bariatric surgery 420
- following spleen injury 199
- incidence and management 202–203
- inferior vena cava (IVC) filter placement 255–256
- management in patients with cirrhosis 210–211
- prophylaxis for total knee or hip replacement 205–206, **206**
- treatment of acute PE 439–440, 440

pulmonary failure, nutritional therapy 186–187

pulmonary physiology, effects of obesity 415

pulmonary trauma, control of pulmonary hemorrhage 444

pulse oximetry monitors, factors affecting the accuracy of readings 59–60

pulseless electrical activity (PEA) arrest 15, 16

pulsus paradoxus, definition and etiologies 20–21

q

quinupristin/dalfopristin, antimicrobial action 104

r

radiocontrast media, contrast-induced nephropathy (CIN) 76

radius, nerve injury in distal radius fractures 324–325

randomization of subjects in a study 488

rapid-sequence intubation

- choice of neuromuscular blocker 122
- drugs used for head-injured trauma patients 72–73

rapid shallow breathing index (RSBI) 64, 86

REBOA (resuscitative endovascular balloon occlusion of the aorta), indications and contraindications in trauma patients 306, 314

rectal bleeding

- colon tumor management 376
- ischemic colitis diagnosis and management 380–381

rectal foreign bodies, removal 383

rectal prolapse, assessment and management 378–379, 378

rectum 371–383

- management of extraperitoneal penetrating trauma 382

re-expansion pulmonary edema, diagnosis and management 445

- following drainage of pulmonary effusion 445

refeeding syndrome (RFS), biochemical derangement in 77

relative risk 487–488

renal dysfunction

- choice of neuromuscular blocking agent 97, **98**
- risk in elderly trauma patients 468–469

renal injuries

- incidence and management in trauma patients 309–310
- pediatric blunt kidney trauma 235
- penetrating renal injury 342–343, 343
- renal exploration for trauma 342–343, 343

- renal replacement therapy
 - advantages over intermittent dialysis 165–166
 - in elderly patients 468–469
 - renal transplant patients
 - common causes of late deaths 212
 - diagnosis of calcineurin toxicity 209–210, **210**
 - diagnosis of renal artery thrombosis 214
 - drug-drug interactions 209–210, **210**
 - post-transplant
 - complications 214
 - side effects of thymoglobulin
 - induction agent 216–217
 - treatment for invasive fungal infection 211
 - renin-angiotensin-aldosterone system 147
 - RESCUEicp trial (2016) findings 197–198
 - research, justification for performing 493
 - RESP score 25–26, **25**
 - respect (ethical principle) 491
 - respiratory acidosis
 - adjustment of ventilator settings 84
 - diagnosis and treatment 142–143
 - respiratory failure management, role of ECMO 87
 - respiratory monitoring 59–67
 - respiratory physiology 3–14
 - resuscitation
 - for hemoperitoneum 118
 - management of continued hypoperfusion 91
 - resuscitation fluids
 - edema promotion effects 143–144
 - effect of normal saline on plasma volume 144
 - normal saline and Plasma-Lyte compared 142
 - resuscitative thoracotomy, indications for 304–305
 - retained hemothorax
 - diagnosis and management 446
 - treatment following blunt chest trauma 306
 - retinol-binding protein, function as a negative acute phase protein 178–179
 - retroperitoneal hematomas,
 - indications for surgical exploration 311–312, *311*
 - retroperitoneal rectal injury,
 - management 337, 338
 - rhabdomyolysis, treatment 162
 - rib fractures
 - incidence and consequences in elderly patients 465–466
 - management in a patient with COPD 80–81
 - management of flail chest 450–451
 - Richmond Agitation and Sedation Scale (RASS) 127, **127**
 - evaluation of delirium tremens **133**, 133
 - right atrial tracing, analysis 8, 9, *10*
 - right internal jugular dual lumen VV ECMO catheter,
 - complications 28–29
 - right-sided heart failure associated with severe hypotension, therapeutic intervention 8, 9
 - right-sided ventricular infarction 45–48, 46, 47
 - risk ratio 487–488
 - rivaroxaban, rapid reversal in trauma patients 118–119, **118**
 - rocuronium
 - mechanism of action 122, 123
 - metabolism and elimination 72, 97, **98**
 - reversal drugs 107–108, *107*
 - Roux-en-Y gastric bypass
 - anastomotic leak detection and treatment 368–369
 - complications 417
 - diagnosis of a perforated marginal ulcer 417
 - diagnosis of acute postoperative obstruction 421
 - diagnosis of postoperative enteric leaks 421–422
 - internal hernia reduction 421
 - internal herniation complication 420–421
 - intraoperative cholecystectomy 417–418
 - intraoperative treatment of gallstones 417–418
 - postoperative nutritional deficiencies 419, 420
 - postoperative pulmonary embolus 420
 - treatment of a perforated marginal ulcer 417
- S**
- salicylate poisoning
 - toxidrome 241–242
 - treatment 241–242
 - sample size for randomized placebo-controlled blind trials 483–484
 - scaphoid bone, management of
 - occult fracture 323
 - scopolamine, antiemetic
 - action 99
 - seat belt mark
 - association with abdominal mesenteric injury 379–380, 379
 - injuries associated with abdominal seat belt sign 310
 - second degree heart block (Mobitz type II) 36–37, 37
 - sedation
 - causes and treatment of hypotension 127
 - optimum level during mechanical ventilation 127, **127**
 - propofol infusion syndrome 125
 - Richmond Agitation and Sedation Scale (RASS) 127, **127**
 - weaning from 121–122
 - seizures, following traumatic brain injury 194
 - Selective Relaxant Binding Agents (SRBAs) 107
 - self-determination principle 491
 - sepsis 51–58
 - diagnostic criteria 51
 - following cystoprostatectomy 339, 339
 - initial management 51
 - major cause of vasodilation 57–58
 - pediatric patient protocolized emergency department sepsis guideline 227
 - resuscitation of pediatric patients 459
 - steroid treatment 146
 - Surviving Sepsis Campaign
 - recommendations 146
 - therapeutics which effectively improve outcomes 56

- sepsis-induced inflammatory cascade,
 - role of the coagulation system 57
- septic pelvic thrombophlebitis,
 - diagnosis and management 223–224
- septic shock
 - combination antibiotic therapy 92–93
 - comparison of epinephrine and dopamine treatment in children 231
 - definition 51
 - early clinical manifestations 74
 - indications for the use of
 - corticosteroids 52
 - Surviving Sepsis Campaign guidelines 231
 - treatment of “cold” shock indicative of cardiovascular dysfunction 55
 - treatment of pediatric fluid-refractory septic shock 231
 - treatment of “warm” or vasodilatory shock 55
 - use of vasoactive agents 91–92
 - use of vasopressin 56–57
- Serratia* species
 - association with CRBSI 63
 - association with VAP 96
 - beta-lactamase production 105
- severe pancreatitis, nutritional therapy 187–188
- severe sepsis
 - combination antibiotic therapy 92–93
 - diagnostic criteria 51
 - early clinical manifestations 74
 - initial management 51
- sevoflurane, potential side effects 124
- Sheehan’s syndrome 148
- shock 15–21
 - early clinical manifestations 74
 - physiologic changes in various types of shock 59
- shock state, relationship between oxygen delivery and oxygen uptake 13–14
- shotgun wounds, type of vascular injuries associated with 334–335
- sigmoid colon volvulus, recurrent 371–372
- silver nitrate antimicrobial, side effects 428
- silver sulfadiazine antimicrobial, side effects 428
- skin and soft tissue infections (SSTIs)
 - most common identifiable cause 411
 - predictor of treatment failure and hospital mortality in MRSA SSTIs 410
 - severe SSTIs caused by diabetic foot infections 413
 - types of 409
- small bowel, mesenteric injury from blunt trauma 379–380, 379
- small intestine 371–383
- smoking, and cardiac risk 49
- snakebite
 - Crotalinae (pit viper) antivenom administration 245–246
 - resolution of compartment syndrome caused by 245–246
- sodium bicarbonate, indications for use 167
- soft tissue infections 409–414
- solid organ injuries
 - management in pediatric patients 463
 - use of anticoagulation 199
- Specific Activity Scale 75
- spinal anesthesia, postdural puncture headache 125–126
- spinal cord injury (SCI)
 - complications of complete spinal cord injury 291–292
 - effects on the reproductive system 291–292
 - function spared with C7 transection 279
 - Jefferson fracture 295, 295
 - pulmonary function testing 288
 - use of high-dose steroids 279–280
- spinal cord injury without radiographic abnormality (SCIWORA), features in children 454–455
- spinal shock
 - distinction from neural shock 21
 - presentation 21
- spleen 398–402
 - anatomy 398
- spleen injury
 - angioembolization 400–401
 - APSA guidelines for pediatric blunt trauma 234–235, 234
 - contraindication to non-operative management 401
 - criteria for nonoperative management 308–309
 - indication for surgical intervention 399–400, 400
 - Jehovah’s Witness patient 401
 - management of 199
 - nonoperative management 263–264
 - pediatric patients 455, 457–458
 - presence of a blush on CT scan 399–400, 400
 - splenic preservation in children 457–458
 - use of angiography in blunt trauma 263–264
 - use of anticoagulation 199
- splenectomy
 - following gunshot wound to the spleen 338–339, 339
 - indications for 401
 - locations for an accessory spleen 398
 - overwhelming postsplenectomy infection (OPSI) risk 401–402
 - predictors of a favorable response 398
 - vaccinations for splenectomy patients 313
- splenic artery aneurysm, diagnosis and management 399
- splenic artery embolization, following blunt trauma 263–264
- splenic blush on CT, pediatric blunt abdominal trauma patients 231
- splenic cyst, classification and management 399
- spontaneous bacterial peritonitis, diagnosis and treatment 172
- ST-elevation myocardial infarction (STEMI), acute stent thrombosis complication 440
- standard deviation (SD) 484
- Staphylococcus aureus*
 - association with CRBSI 63
 - association with NSTIs 94–95
 - see also MRSA

- Staphylococcus epidermidis*
 association with CRBSI 63
 treatment of catheter-related
 bloodstream infection 53
- Stark Laws 497
- Starling equation 14
- statin therapy, use in the
 perioperative period
 73–74
- statistics 483–489
- stent, patient with
 effect on subsequent non-cardiac
 surgery 75
 perioperative management of
 antiplatelet medications
 116–117
- steroid therapy
 use in blunt traumatic brain
 injury 189
 use in sepsis 146
- steroid-treated patients
 interventions to improve wound
 healing 149–150
 symptoms of bowel injury 149
- stomach 359–369
- stratified randomization 488
- streptococcal toxic shock
 syndrome, choice of
 antibiotic 107
- Streptococcus pneumoniae*,
 association with VAP 96
- Streptococcus pyogenes*, association
 with NSTIs 94–95
- stress and injury, phases of response
 to 177
- stress ulcers in high-risk ICU
 patients, factors associated
 with increased incidence
 74–75
- stroke volume, factors
 determining 4, 4
- stroke volume variability (SVV)
 factors affecting 60
 normal range of variation 60
- Student's t-test 485
- subarachnoid hemorrhage (SAH),
 symptoms and management
 282–283
- subclavian artery injury
 commonly associated injuries
 301–302
 concomitant venous injury
 301–302
 management 302
- subdural hematoma
 causes and management 282
 incidence and risk factors 282
- subarachnoid hemorrhage, secondary
 to ruptured cerebral artery
 aneurysm 192
- substituted judgment 491
 in end-of-life care 493–494
- succinylcholine
 action as NMBA 107
 contraindication for burn
 victims 122
 mechanism of action 122, 123
 method of elimination 97, **98**
 risk of hyperkalemia and cardiac
 arrest 137
- sugammadex, mechanism of
 action 107–108, 107
- suicidal hanging (non-lethal), common
 presenting injuries 291
- suicide, rates among the elderly 471
- sulfamylon acetate antimicrobial, side
 effects 427–428
- sulfonylurea overdose, symptoms and
 treatment 244–245
- superior mesenteric artery (SMA)
 treatment of penetrating trauma
 injury 373–374
 zones of the SMA 374
- superior vena cava (SVC) syndrome,
 diagnosis and management
 446–447
- supra-glottal airway devices (SADs),
 role in tracheal intubation
 293–294
- surgeon autonomy 495–496
- surgery
 anticoagulation management
 33–34, **34**
 prognostic models 169, **170**
- surgery (non-cardiac)
 assessment for cardiovascular
 perioperative risk 75
 in patients that have received
 PCI 75
- surrogate decision-making for
 patients 469–470
- Surviving Sepsis Campaign
 guidelines 91, 92, 146
 for pediatric patients 459
- syncope
 history of 36–37, 37
 prevalence and etiologies in elderly
 people 473
- syndrome of inappropriate
 antidiuretic hormone
 (SIADH), diagnosis and
 treatment 148–149
- synthetic marijuana (Spice/K2),
 mechanism of action 250–251
- systemic inflammatory response
 syndrome (SIRS)
 causes and treatment 20
 diagnostic criteria 20, 51
- systemic vascular resistance (SVR)
 calculation 67
 definition 67
- t-test 484
- t**
- tachycardia, diagnosis 34–35, 34
- tacrolimus
 drug-drug interactions
 209–210, **210**
 immunosuppression in transplant
 patients 210
 mechanism of action 214–215
 side effects 215
- Takotsubo's syndrome 36
- tazobactam, antimicrobial activity
 105–106
- telemedicine and telepresence for
 surgery and trauma 477–481
 applications for surgical
 telementoring 477–478
 benefits of implementation in
 critical care units 481
 electronic data communications
 networks 477
 real-time trauma
 resuscitation 480–481
 teletrauma support 479–480
 virtual intensive care 478–479
- temperature management,
 intravascular versus surface
 cooling 157
- temporary abdominal closure (TAC),
 methods and considerations
 312–313
- temporary intravascular shunt (TIVS)
 duration of placement 329–330
 in combined skeletal and arterial
 injuries 333–334, 334
 purpose of 329–330
- tension pneumothorax
 diagnosis and management 447
 effect on central venous pressure
 (CVP) 66

- tetanus, treatment for patients at risk 54
- therapeutic hypothermia, indications and contraindications 155
- thermodilution principle, use in pulmonary artery catheter 62–63
- thiopental, mechanism of action 128
- thoracic surgery 439–451
- thoracic vascular injury 299–306
- thoracotomy, indications for urgent/emergent thoracotomy 303
- thrombocytopenia, heparin-induced (HIT) 100–101, 115–116
- thromboelastography (TEG), use of rapid TEG in trauma patients 112, 112
- thromboembolism 199–208
- thrombolytics, use in acute coronary syndromes 48
- thrombosed external pile, diagnosis and management 381–382
- thrombotic thrombocytopenic purpura (TTP), pregnant patient 222–223
- thumb, replantation of traumatic amputations 323–324
- thymoglobulin, side effects when used as induction agent 216–217
- thyroid storm, etiologies, symptoms and management 148
- tibia and fibula fracture
 - indication for below-knee amputation 320
 - indications of compartment syndrome 321
 - limb salvage versus amputation 320
 - pain following splinting 321
- tibia fracture
 - fasciotomy incision to decompress the leg compartments 322, 322
 - infection risk in open fractures 319–320, 319
 - timing of debridement of open fractures 320
- tigecycline
 - black box warning 108
 - risk of death 108
 - use in refractory *C. difficile* infection 100
- time-to-event analysis 488–489, 489
- Tobin index 86
- tocolytic associated pulmonary edema 226
- torsade de pointes 41–42, 41–42
- total parenteral nutrition (TPN)
 - constituents of 185
 - efficacy in critically-ill and injured patients 181–182
 - formulas 180
 - guidelines on lipid use 182
 - hypophosphatemia risk 141–142
 - indications for the use of 180–181
 - prophylactic antibiotics 93
 - refeeding syndrome 141–142
- tourniquet, use to control active bleeding 328–329
- toxic shock syndrome, choice of antibiotic 107
- toxicology 239–251
- toxidromes
 - management strategies 240–241
 - salicylate poisoning 241–242
 - signs for specific drug classes 240–241
- tracheal injury
 - airway management 297
 - “clothesline” injury management 297
 - penetrating injury 289–290
 - tracheal laceration repair 292
- tracheal intubation, actions following several failed attempts 293–294
- tracheoesophageal fistula (TEF)
 - diagnosis and management 448–449
 - in intubated patients 448–449
- tracheo-innominate fistula (TIF)
 - diagnosis and treatment 445–446
 - risk factors in tracheostomy 294–295
- tracheostomy
 - bleeding after the first 48 hours 445
 - choice of technique 256–257
 - complication rates in obese patients 416
 - management of a dislodged tracheostomy tube 84
 - ongoing hemorrhage from 445–446
- potential early and late complications 257
- risk factors for tracheo-innominate fistula 294–295
- tranexamic acid (TXA), use in trauma patients 110–111
- transferrin, function as a negative acute phase protein 178–179
- transfusion 109–119
 - activation of massive transfusion protocol (MTP) 111–112
 - blood component therapy 109
 - definition of massive transfusion 111–112
 - effects of liberal transfusion with PRBCs 111
 - plasma for patient of unknown blood type 112–113
 - PRBC transfusion in pediatric critically-ill patients 228–229
 - prophylactic transfusion in trauma patients 109–110
 - ratio and type of platelets 113
 - respiratory distress during or after 110
 - restrictive transfusion strategy 109–110
 - stable trauma patient without active bleeding 109–110
 - use of rapid thromboelastography (TEG) in trauma patients 112, 112
 - use of uncrossmatched type O blood in trauma patients 118
 - see also* massive transfusion
- transfusion-associated acute lung injury (TRALI) 110
- transfusion-associated circulatory overload (TACO) 110
- transjugular intrahepatic portosystemic shunt (TIPS)
 - stent stenosis risk 171
 - use in intractable ascites 173
- transplantation 209–217
 - hyperacute rejection 213–214
 - treatment of cytomegalovirus (CMV) infection 215–216
- transthoracic echocardiography (TTE), assessment of pericardial effusion 261
- trans-tracheal jet ventilation (TTJV) 293–294

- trauma patients
 - risk factors for developing pneumonia 94
 - use of tranexamic acid (TXA) 110–111
 - traumatic brain injury (TBI)
 - avoiding secondary brain injury 191
 - Brain Injury Guidelines (BIG) 284–285, **285**
 - brain oxygenation monitoring techniques 195
 - Brain Trauma Foundation management guidelines 198
 - criteria for brain death declaration 494–495
 - decompressive craniectomy 283–284
 - decreasing ICP without lowering BP 284
 - disruption of cerebral autoregulation 196
 - effects of fever in neurological injury 156
 - identification in pediatric patients 463–464
 - initial management of acute head injury 277–279
 - initial treatment of severe TBI 280
 - intracranial pressure (ICP) monitoring 279
 - management guidelines 191
 - management of anticoagulated patients 285–286
 - management of cerebral perfusion pressure 196
 - management of elevated ICP in pediatric patients 196–197
 - management of small injuries 284–285, **285**
 - management using Brain Injury Guidelines (BIG) 284–285, **285**
 - objective of ICP monitoring 189–190
 - optimizing ICP and cerebral perfusion pressure (CPP) 283–284
 - predictor of poor outcome in gunshot wound to the brain 191–192
 - pregnant trauma patient 348
 - recommended target cerebral perfusion pressure 280
 - role of steroid therapy 189
 - seizures following 194
 - therapy for increased intracranial pressure (ICP) 280–281
 - use of barbiturate therapy 194–195
 - use of hypertonic saline 284
 - use of progesterone therapy 196
 - VTE risk and prophylaxis 283
 - traumatic diaphragmatic hernia (TDH), causes and presentation 299
 - traumatic head injury, drugs for rapid-sequence intubation 72–73
 - traumatic venous injury, options for repair 332
 - tricuspid regurgitation, right atrial tracing 8, 9, 10
 - tricyclic antidepressants (TCA)
 - clinical presentation of TCA toxicity in overdose 239–240
 - management of TCA overdose 471
 - suicide risk in elderly people 471
 - triple contrast CT scan, indications and contraindications 267–268
 - Trousseau sign 145
 - tubocurarine, metabolism and elimination 72
 - Type I error 485
 - Type II error 485
 - typhlitis, complication of chemotherapy 374–375
- u**
- ultrasound 261–272
 - guidance for central venous catheter (CVC) placement 270–271
 - use in initial assessment of trauma patients 262
 - umbilical hernia
 - fluid leakage in patient with cirrhosis 404–405
 - incarcerated/strangulated 381
 - reduction of incarceration and repair 403
 - unfractionated heparin (UFH) anticoagulation 99–100
 - United States Uniform Anatomic Gift Act 496
 - unrecognised misplaced intubation (UMI), identifying 64–65
- uremic bleeding, coagulopathy in uremic patients 116
- ureteral injury from gunshot wound, treatment options 341–342, **342**
- urethral injury
 - diagnosis in trauma patients 308
 - indications and investigation 337–338, 339
 - management of anterior and posterior urethral injuries 340
- urinary tract infection (UTI), risk factors in catheterized patients 93–94
- urologic trauma and disorders 337–343
- v**
- valproic acid overdose, symptoms and management 246
- vancomycin
 - antimicrobial action 104
 - use in refractory *C. difficile* infection 100
 - use in VAP 104–105
- vancomycin-resistant *Enterococcus* (VRE), association with VAP 96
- vascular injury
 - abdominal 307–315
 - evaluation and management 327
 - hard and soft signs 327
 - thoracic 299–306
- vascular resistance, definition 67
- vasoconstriction, role of endothelin-1 in cardiogenic shock 58
- vasodilation
 - cause in sepsis 57–58
 - effects of nitric oxide (NO) 57–58
 - effects of vasodilators on cardiac function 3
 - mechanism of action of dobutamine 62
- vasopressin 15
 - role in septic shock management 56–57, 91–92
- vasopressor-dependent septic shock, use of corticosteroids 52
- vecuronium
 - mechanism of action 122, 123
 - metabolism and elimination 72, **98**
 - reversal drugs 107–108

- venous access catheters, factors
 - influencing optimal rate of volume resuscitation 3, 4
 - venous thromboembolism (VTE)
 - ACCP prevention and treatment guidelines 205, 206
 - characteristics of VTE in pregnancy 223
 - incidence in the SICU 207
 - risk factors in pediatric patients 463
 - risk factors in pediatric trauma patients 232–233
 - risk in pregnancy and post-partum 201–202
 - venous thromboembolism (VTE) prophylaxis
 - criteria in pediatric patients 463
 - enoxaparin dosing and monitoring 207
 - in traumatic brain injury patients 283
 - ventilated patient, oxygen uptake/ consumption (VO_2)
 - calculation 18
 - ventilator-associated pneumonia (VAP)
 - choice and dose of antimicrobial agent 104
 - common causative organisms 55, 96
 - diagnosis 81
 - diagnostic criteria for quantitative microbiology 52
 - diagnostic use of bronchoscopy 258
 - duration of antibiotic therapy 90
 - empiric therapy 96
 - Infectious Disease Society of America (IDSA) guidelines for management 104–105, **104**
 - pathogens associated with early-onset VAP 52
 - prevention bundles 91
 - risk factors for MDR pneumonia 96
 - risk factors in the pediatric ICU 232
 - risk of multidrug resistant (MDR) pathogens 104–105, **104**
 - sources of causative bacteria 53
 - use of hospital antibiograms 104
 - ventilator support 79–88
 - addressing “bird’s beak” pressure-volume curve 88, 88
 - cardiopulmonary interactions 12–13
 - findings before postoperative spontaneous breathing begins 83
 - indicators for successful liberation from support 64
 - intraoperative ventilatory settings 83
 - management of respiratory acidosis 84
 - managing elderly patients 466
 - optimal level of sedation 127, **127**
 - parenchymal-pleural fistula (PPF) management 82
 - rapid shallow breathing index (RSBI) 64
 - waveform analysis 87, 87
 - ventilator tidal volume setting for obese patients 416
 - ventral hernia, principles for repair 405
 - ventricular fibrillation
 - Brugada syndrome 35–36, 35
 - following myocardial infarction 49–50, 49
 - ventriculoseptal defect (VSD), post-myocardial infarction 44–45, 45
 - ventriculostomy, management of elevated intracranial pressure 190
 - ventriculostomy catheters, incidence of infection from 192–193
 - vertebral artery, management of traumatic injury 295–296, 295
 - Vibrio* species, diagnosis of NSTI caused by 412
 - Vibrio vulnificus*
 - association with NSTIs 94–95
 - symptoms and treatment of infection from seafood 211–212
 - video laryngoscopy, effect on first-chance intubation success rate 70
 - violence towards pregnant women, risk factors and consequences 435
 - virtue ethics 492–493, 495
 - vitamin B12 deficiency, risks related to nitrous oxide anesthesia 124
 - volume-cycled ventilation (VCV), prolonging the inspiratory time 81–82
 - volume resuscitation, management of continued hypoperfusion 91
 - volume status
 - indicators 60
 - management in trauma patients 340
 - vomiting, acid-base and electrolyte abnormalities caused by 136
 - VTE *see* venous thromboembolism
- W**
- warfarin anticoagulation
 - rapid reversal in trauma patients 114
 - use in elderly trauma patients 466–467
 - weaning from sedation 121–122
 - Wells score for PE diagnosis 204
 - West lung zones 12
 - Westermarck sign 80
 - whole bowel irrigation (WBI), prevention of absorption of drugs 239
 - Wilcoxon Rank Sum test 484, 485
 - Wolff–Parkinson–White syndrome 34–35, 34
 - wound healing, impairment in steroid-treated patients 149–150
 - wrist injury, factors leading to poor outcomes 325
 - wrist pain
 - occult scaphoid fracture 323
 - without acute radiographic findings 323
 - wrong-site surgical procedures
 - protocol to prevent 73
 - risk factors for 73
- X**
- Xarelto *see* rivaroxaban
 - X-ray, use in pelvic fracture diagnosis 271